Stem Cells/Wnt

Zamaporvint (RXC004) is an orally active and selective Wnt pathway inhibitor that targets the membrane-bound O-acyltransferase Porcupine. By inhibiting Wnt ligand palmitoylation, it blocks Wnt ligand secretion and downstream pathway activation. Zamaporvint exhibits a favorable pharmacokinetic profile and shows potent antiproliferative activity in Wnt ligand-dependent colorectal and pancreatic cancer cell lines. With multiple antitumor mechanisms, it is a promising agent for cancer research.

CCT036477 is a selective inhibitor of the Wnt/β-catenin signaling pathway that effectively disrupts β-catenin-mediated transcription without affecting its overall levels. This compound demonstrates significant anti-proliferative effects on various cancer cell lines and impairs embryonic development. Additionally, CCT036477 downregulates the expression of key Wnt target genes, including PPARδ, Cyclin D1, TCF4, and ID2, making it a valuable tool for research in cancer biology and developmental studies.

Chikusetsusaponin IVa methyl ester is a natural triterpenoid saponin that functions as a Wnt/β-catenin, NF-κB, and AP-1 inhibitor. It induces G0/G1 cell cycle arrest and apoptosis in colon cancer cells through the inhibition of the Wnt/β-catenin signaling pathway. Additionally, this compound significantly decreases the production of nitric oxide, prostaglandin E₂, and pro-inflammatory cytokines, while downregulating iNOS and COX-2 levels. Chikusetsusaponin IVa methyl ester is valuable for research focused on colorectal cancer and inflammatory processes.

Windorphen is a selective Wnt/β-catenin signaling inhibitor that specifically interferes with the c-terminal transactivation domain of β-catenin-1, while leaving β-catenin-2 unaffected. This compound targets p300, effectively disrupting the interaction between β-catenin and p300 without impacting CBP. Windorphen is valuable for research applications focused on β-catenin-related pathways, cancer biology, and developmental processes.

WNT7A-IN-1 sodium is a selective inhibitor of WNT7A that disrupts the interaction between WNT7A and its receptor FZD5, leading to enhanced expression of MHC-I. This reagent is known to significantly increase levels of MHC-I and phosphorylated p65 while decreasing active β-catenin expression. Additionally, WNT7A-IN-1 sodium acts as a photosensitizer in the green spectral region, making it suitable for applications in photodynamic therapy and immunological studies.

Wnt Pathway Inhibitor 3 is a potent inhibitor of the Wnt signaling pathway, exhibiting an IC50 value of 45 nM. This compound demonstrates significant antiproliferative activity, making it a valuable tool for research in cancer biology and developmental studies. Its ability to modulate Wnt signaling can aid in the exploration of various cellular processes and disease mechanisms.

JW67 is a potent Wnt signaling inhibitor that targets the multiprotein complex composed of β-catenin, GSK-3β, AXIN, APC, and CK1, demonstrating an IC50 of 1.17 µM. By effectively reducing active β-catenin levels, JW67 leads to the downregulation of Wnt target genes, making it a valuable tool for studying Wnt signaling pathways. Additionally, JW67 inhibits the growth of colorectal cancer cells, providing potential applications in cancer research and therapeutic development.

Ipafricept is a recombinant fusion protein that functions as a Wnt inhibitor by binding to Wnt ligands via the extracellular portion of the human Frizzled-8 receptor fused with a human IgG1 Fc fragment. This mechanism effectively blocks Wnt signaling pathways, leading to reduced tumor growth and decreased liver and lung metastases when combined with Gemcitabine in pancreatic cancer mouse models. Additionally, Ipafricept demonstrates significant inhibitory activity against solid tumors, including desmoid tumor, germ cell cancer, and ovarian cancer, with an acceptable tolerance profile.

Coronaridine is an iboga alkaloid that functions as a Wnt signaling pathway inhibitor, effectively reducing β-catenin expression. This compound is primarily employed in research related to cancer biology, stem cell differentiation, and developmental processes, where dysregulation of the Wnt pathway is implicated. Its ability to modulate β-catenin levels makes it a valuable tool for investigating the mechanistic roles of Wnt signaling in various biological contexts.

WIC1 is a potent Wnt signaling inhibitor that targets the Wnt pathway, crucial for various biological processes, including cell proliferation and differentiation. This compound demonstrates significant anti-cancer activity by disrupting Wnt-mediated transcriptional activation, making it valuable for cancer research. WIC1 can be utilized in investigations of tumor growth, metastasis, and the overall role of Wnt signaling in oncogenesis.

Gigantol isomer-1 is a bibenzyl compound that functions as a Wnt inhibitor. This compound demonstrates significant therapeutic potential by targeting cancer cell proliferation and survival through modulation of the Wnt/β-catenin signaling pathway. Its capability to disrupt this crucial pathway makes it a valuable tool for research applications focused on cancer biology and therapeutic development.

SJ26 is a potent Wnt1 inhibitor that exhibits anticancer activity. By targeting and inhibiting the expression of Wnt1, SJ26 disrupts Wnt1-mediated downstream signaling pathways, leading to a reduction in the migratory capacity of cancer cells. This compound is valuable for research focused on cancer progression and the role of Wnt signaling in tumor metastasis.

15-Oxospiramilactone is a diterpene derivative that functions as a Wnt/β-catenin signaling inhibitor. It exhibits significant biological activity by suppressing tumorigenesis in colon cancer cells, making it a valuable reagent for cancer research. This compound is suitable for studies investigating the modulation of the Wnt pathway and its implications in colorectal cancer progression.

WNT7A-IN-1 is a WNT7A inhibitor that disrupts the interaction between WNT7A and its receptor FZD5, leading to the upregulation of MHC-I expression. This compound enhances the expression of MHC-I and phosphorylated p65 while decreasing the levels of active β-catenin. Additionally, WNT7A-IN-1 serves as a photosensitizer in the green spectral region, making it valuable for research in cancer immunotherapy and photodynamic therapy applications.

Wnt Pathway Inhibitor 5 is a potent inhibitor of the Wnt signaling pathway, exhibiting an IC50 value of less than 0.003 µM. This compound demonstrates significant anti-cancer activity, making it effective against various malignancies such as ovarian teratocarcinoma, breast cancer, osteosarcoma, and head and neck squamous carcinoma. It serves as a valuable tool for researchers investigating the role of Wnt signaling in cancer progression and therapeutic interventions.

IWP-2-V2 is an analogue of IWP-2 that effectively inhibits the Wnt/β-catenin signaling pathway. This compound plays a significant role in modulating cellular processes related to development and cancer, making it a valuable tool for researchers studying the implications of Wnt signaling in various biological contexts. Its ability to disrupt β-catenin-mediated transcriptional activity positions IWP-2-V2 as a potential candidate for investigations into regenerative medicine and cancer therapy.

SEN461 is a potent and orally bioavailable inhibitor of the Wnt signaling pathway. This compound demonstrates significant anti-tumor activity, making it a valuable tool for research applications in glioblastoma multiforme (GBM) and other cancers driven by aberrant Wnt pathway activation. Its efficacy in modulating Wnt-related processes highlights its potential for therapeutic development and mechanistic studies in cancer biology.

21H7 is a selective inhibitor of the Wnt/β-catenin signaling pathway. This compound significantly inhibits cell proliferation in hair follicles and demonstrates potent growth suppression of breast and colon cancer cells. Due to its specific targeting of the Wnt/β-catenin pathway, 21H7 serves as a valuable tool in cancer research and therapeutic development.

Wnt/β-catenin-IN-7 is a Wnt signaling pathway inhibitor with an IC50 of 0.15 μM. This compound effectively disrupts β-catenin-mediated transcriptional activation, making it valuable for investigating the role of Wnt signaling in cancer and fibrosis. Its potent inhibitory activity supports research into therapeutic targets within these pathological conditions.

Wnt/β-catenin-IN-4 is a potent inhibitor of the Wnt/β-catenin signaling pathway. This compound effectively disrupts β-catenin-dependent transcription, making it a valuable tool for investigating the role of Wnt signaling in various biological processes. It is commonly utilized in cancer research, developmental biology, and studies related to stem cell differentiation.